Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766536 | 0.89 | HDAC1 (0.52) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6762133 | 0.87 | POLB (0.53) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6571948 | 0.84 | HDAC1 (0.48) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6771080 | 0.83 | F2 (0.51) | HDAC1HDAC8MCL1METAP2 | |
| SCHEMBL6571770 | 0.82 | RORC (0.50) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6767177 | 0.81 | HDAC1 (0.51) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6569935 | 0.81 | MCL1 (0.49) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6574016 | 0.81 | HDAC1 (0.51) | HDAC1HDAC8RORCMCL1KDM1A | |
| SCHEMBL6571783 | 0.80 | LMNA (0.51) | HDAC1HDAC8RORCKDM1ALMNA | |
| SCHEMBL6570647 | 0.80 | MCL1 (0.54) | HDAC1HDAC8RORCMCL1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | HDAC1 696/4885HDAC8 723/4885RORC 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.